Needham & Company LLC started coverage on shares of Trulieve Cannabis (OTCMKTS:TCNNF) in a report issued on Tuesday morning, The Fly reports. The brokerage issued a buy rating and a $20.00 target price on the stock.
Separately, Compass Point raised Trulieve Cannabis from a neutral rating to a buy rating and increased their target price for the company from $11.00 to $17.00 in a research note on Monday.
Trulieve Cannabis stock opened at $13.13 on Tuesday. Trulieve Cannabis has a fifty-two week low of $6.68 and a fifty-two week high of $16.23. The firm’s fifty day moving average price is $10.94 and its 200-day moving average price is $10.19.
Trulieve Cannabis Corp. operates as a medical marijuana company. The company cultivates and produces products in-house and distributes its products to Trulieve branded stores (dispensaries) in Florida, as well as directly to patients via home delivery. It produces approximately 150 stock keeping units, including nasal sprays, capsules, concentrates, syringes, cannabis flower in tamper-proof containers for vaporizers, topical creams, tinctures, and vape cartridge.
Featured Story: How to start trading in the forex market?
Receive News & Ratings for Trulieve Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trulieve Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.